France· FR:67455336
NEPRESSOL 25 mg/2 ml, poudre et solvant pour solution injectable
A dihydralazine product containing mésilate de dihydralazine, registered in France by EFISCIENS (MALTE). The same ATC class is registered in 4 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Dihydralazine is registered in 4 of 19 countries.
Countries holding a registration under ATC C02DB01 (dihydralazine), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 3 of them publish a price we can compare per daily dose
Dihydralazine · ATC C02DB01
4 / 19 countries
- Finlandprice
- Franceprice
- Germany
- Norwayprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MÉSILATE DE DIHYDRALAZINE
- Manufacturer
- EFISCIENS (MALTE)
- Country
- France (FR)
- ATC code
- C02DB01
- ATC class
- Dihydralazine
- Defined daily dose
- 75 mg, O
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009562411325 ampoule(s) de poudre en verre de 25 mg - 5 ampoule(s) de solvant en verre de 2 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dihydralazine in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Germany · Nepresol
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d8ded8a9-9ce9-421c-8356-da4e0cd57639 GET /v1/drugs/d8ded8a9-9ce9-421c-8356-da4e0cd57639?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67455336",
"date_amm": "2000-05-19",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "MÉSILATE DE DIHYDRALAZINE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre et solvant pour solution injectable",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about dihydralazine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.